Abstract | BACKGROUND: This study examined real-world patients with locally advanced or metastatic urothelial carcinoma (advUC) considered ineligible for platinum-containing chemotherapy in the first-line (1 L) setting. METHODS: This retrospective observational study used data from a nationwide (US) de-identified patient-level electronic health record-derived database. Eligible adults (≥18 years) had an advUC diagnosis on or after January 1, 2016, and initiated 1 L systemic treatment ≥90 days before December 31, 2021. Platinum ineligibility was defined as ECOG performance status ≥3, creatinine clearance <30 mL/min, or ECOG performance status of 2 and creatinine clearance <45 mL/min. Overall survival (OS) and real-world progression-free survival (PFS) were summarized using the Kaplan-Meier method. RESULTS: CONCLUSION: This real-world study has shown for the first time the treatment patterns and outcomes in newly diagnosed patients with advUC ineligible for platinum-based chemotherapy. These findings provide quantitative benchmarks for platinum ineligibility in the 1 L advUC setting and highlight the need for novel therapy options.
|
Authors | Shilpa Gupta, Alexander Andreev-Drakhlin, Otto Fajardo, Marcella Fassò, Jorge A Garcia, Christopher Wee, Carsten Schröder |
Journal | Journal of the National Cancer Institute
(J Natl Cancer Inst)
(Nov 30 2023)
ISSN: 1460-2105 [Electronic] United States |
PMID | 38036464
(Publication Type: Journal Article)
|
Copyright | © The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected]. |